CY1109245T1 - Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα - Google Patents

Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα

Info

Publication number
CY1109245T1
CY1109245T1 CY20091100772T CY091100772T CY1109245T1 CY 1109245 T1 CY1109245 T1 CY 1109245T1 CY 20091100772 T CY20091100772 T CY 20091100772T CY 091100772 T CY091100772 T CY 091100772T CY 1109245 T1 CY1109245 T1 CY 1109245T1
Authority
CY
Cyprus
Prior art keywords
unions
suspension
useful
carbon treatment
death factor
Prior art date
Application number
CY20091100772T
Other languages
English (en)
Inventor
Yusheng Xiong
Kevin Chapman
Suresh Singh
Jian Guo
Arthur A Patchett
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29711965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109245(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of CY1109245T1 publication Critical patent/CY1109245T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/32—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

Η εφεύρεση αυτή αφορά ενώσεις του τύπου (Ι), και μέθοδο για θεραπεία άνθρακα ή αναστολή θανατηφόρου παράγοντα δια χορήγησης σύνθεσης που περιέχει ένωση του τύπου (Ι) και φαρμακευτικώς αποδεκτό φορέα. Η εφεύρεση αυτή περαιτέρω αφορά την χρήση ενώσεων του τύπου (Ι) για την θεραπεία άλλων καταστάσεων που σχετίζονται με μόλυνση από άνθρακα.
CY20091100772T 2002-05-29 2009-07-20 Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα CY1109245T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38399602P 2002-05-29 2002-05-29
EP03734152A EP1511472B1 (en) 2002-05-29 2003-05-23 Compounds useful in the treatment of anthrax and inhibiting lethal factor

Publications (1)

Publication Number Publication Date
CY1109245T1 true CY1109245T1 (el) 2014-07-02

Family

ID=29711965

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100772T CY1109245T1 (el) 2002-05-29 2009-07-20 Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα

Country Status (28)

Country Link
US (1) US7504425B2 (el)
EP (1) EP1511472B1 (el)
JP (1) JP4002927B2 (el)
KR (1) KR100701811B1 (el)
CN (1) CN100475206C (el)
AT (1) ATE429909T1 (el)
AU (1) AU2003239599B8 (el)
BR (1) BR0311136A (el)
CA (1) CA2487727C (el)
CY (1) CY1109245T1 (el)
DE (1) DE60327432D1 (el)
DK (1) DK1511472T3 (el)
EC (1) ECSP045452A (el)
ES (1) ES2323527T3 (el)
HR (1) HRP20041138A2 (el)
IL (2) IL165259A0 (el)
IS (1) IS7517A (el)
MA (1) MA27257A1 (el)
MX (1) MXPA04011767A (el)
NO (1) NO329290B1 (el)
NZ (1) NZ536189A (el)
PL (1) PL374117A1 (el)
PT (1) PT1511472E (el)
RU (1) RU2289575C2 (el)
SI (1) SI1511472T1 (el)
UA (1) UA76059C2 (el)
WO (1) WO2003101382A2 (el)
ZA (1) ZA200408650B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101382A2 (en) 2002-05-29 2003-12-11 Merck & Co., Inc. Compounds useful in the treatment of anthrax and inhibiting lethal factor
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CN1950354A (zh) * 2004-05-11 2007-04-18 默克公司 N－磺酰化－氨基酸衍生物的制备方法
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
WO2007117981A2 (en) * 2006-03-29 2007-10-18 Novartis Ag Selective hydroxamate based mmp inhibitors
US7807720B2 (en) 2007-02-01 2010-10-05 Panthera Biopharma, Llc Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning
WO2008094592A1 (en) 2007-02-01 2008-08-07 Panthera Biopharna, Llc Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning
WO2009008905A1 (en) * 2007-02-01 2009-01-15 Panthera Biopharma, Llc. Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
US8119692B2 (en) 2007-04-02 2012-02-21 Panthera Biopharma Llc Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning
EP2662353A3 (en) * 2007-06-12 2014-04-02 Achaogen, Inc. Antibacterial agents
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
CN101503475B (zh) * 2009-03-12 2013-06-19 中国人民解放军军事医学科学院生物工程研究所 炭疽致死因子结构域(LFn)与炭疽水肿因子结构域(EFn)的融合蛋白及其应用
EP2847168A1 (en) 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents
CN111377849A (zh) * 2018-12-28 2020-07-07 中国人民解放军军事科学院军事医学研究院 化合物、其可药用盐及其医药用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK165665C (da) 1984-10-15 1993-06-14 Sankyo Co Laegemiddel indeholdende et penem- eller carbapenemantibiotikum og et aminosyrederviat
EP0272787B1 (en) 1986-11-14 1992-05-06 Takasago International Corporation Catalytic production of optically active carboxylic acid
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5171892A (en) 1991-07-02 1992-12-15 E. I. Du Pont De Nemours And Company Chiral phospholanes via chiral 1,4-diol cyclic sulfates
GB9202298D0 (en) 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
US5677274A (en) 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US5591631A (en) 1993-02-12 1997-01-07 The United States Of America As Represented By The Department Of Health And Human Services Anthrax toxin fusion proteins, nucleic acid encoding same
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JPH11511137A (ja) * 1995-08-08 1999-09-28 ファイブロゲン，インコーポレーテッド コラーゲンの過剰生産に関係した疾患を治療するためのｃ−プロテイナーゼ阻害剤
ATE226936T1 (de) 1995-08-08 2002-11-15 Ono Pharmaceutical Co Hydroxamsäurederivate verwendbar zur hemmung von gelatinase
AU715764B2 (en) 1996-01-23 2000-02-10 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
CA2242416C (en) 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
AU4812697A (en) * 1996-10-22 1998-05-15 Pharmacia & Upjohn Company Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
AU5426398A (en) * 1996-10-28 1998-05-22 Versicor Inc Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
JPH10204059A (ja) 1997-01-22 1998-08-04 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
ZA98376B (en) 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
EP0977745B1 (en) 1997-03-04 2004-12-01 Pharmacia Corporation Thioaryl sulfonamide hydroxamic acid compounds
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
JPH1135557A (ja) 1997-07-17 1999-02-09 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
TR200100389T2 (tr) 1997-07-22 2001-08-21 Shionogi & Co., Ltd., Glomerulpatinin tedavisi veya önlenmesi için terkip.
NZ503945A (en) * 1997-07-31 2002-11-26 Procter & Gamble Metalloprotease-inhibiting amide derivatives
CA2306460A1 (en) 1997-11-14 1999-05-27 G.D. Searle & Co. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
HUP0101176A3 (en) * 1998-02-04 2002-06-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
JPH11246527A (ja) 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
CA2324379C (en) 1998-04-01 2012-12-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Anthrax lethal factor is a mapk kinase protease
PL343361A1 (en) * 1998-04-03 2001-08-13 Sankyo Co Sulfonamide derivatives
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
ATE357516T1 (de) 1998-05-12 2007-04-15 Isis Pharmaceuticals Inc Modulation molekularer wechselwirkungspositionen in rns und anderen biomolekülen
WO2000015213A1 (fr) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Agent de prevention ou de traitement de l'insuffisance cardiaque congestive
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
FR2798291B1 (fr) 1999-09-10 2005-01-14 Pasteur Institut Compositions acellulaires immunogenes et compositions acellulaires vaccinales contre bacillus anthracis
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6465508B1 (en) 2000-02-25 2002-10-15 Wyeth Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
KR100440501B1 (ko) * 2000-03-16 2004-07-15 주성엔지니어링(주) 반도체 소자의 게이트 산화막 형성방법
DE10014063A1 (de) 2000-03-22 2001-09-27 Kaltenbach & Voigt Medizinischer oder dentalmedizinischer Behandlungsstuhl oder eine Kopfstütze für einen solchen Behandlungsstuhl
US6277877B1 (en) 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
DE60018085T2 (de) 2000-12-22 2005-07-07 Institut Pasteur Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden
ES2345977T3 (es) 2001-03-14 2010-10-07 Novartis Ag Derivados de acido acetico azacicloalquil sustituidos para uso como inhibidores de mmp.
US7282580B2 (en) 2001-03-29 2007-10-16 Council Of Scientific And Industrial Research Protein molecule useful for inhibition of anthrax toxin
JP4219810B2 (ja) 2001-10-26 2009-02-04 塩野義製薬株式会社 Ｍｍｐ阻害作用を有するスルホンアミド誘導体
US7763451B2 (en) 2001-11-09 2010-07-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing Bacillus anthracis protective antigen for use in vaccines
EP1461313B1 (en) 2001-12-14 2009-08-05 Exelixis, Inc. Human adam-10 inhibitors
US6927068B2 (en) 2002-01-30 2005-08-09 The United States Of America As Represented By The Secretary Of The Navy Rapid and non-invasive method to evaluate immunization status of a patient
US20040006040A1 (en) 2002-02-14 2004-01-08 Pyro Pharmaceuticals, Inc. Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor
WO2003073066A2 (en) 2002-02-25 2003-09-04 Merck & Co., Inc. Reagents and methods for assaying bacillus anthracis lethal factor protease
US20030224403A1 (en) 2002-02-27 2003-12-04 Popov Serguei G. Lethal toxin cytopathogenicity and novel approaches to anthrax treatment
WO2003101382A2 (en) 2002-05-29 2003-12-11 Merck & Co., Inc. Compounds useful in the treatment of anthrax and inhibiting lethal factor
US6803379B2 (en) 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
US7247724B2 (en) 2002-07-25 2007-07-24 Wilex Ag Method for the production of phenylalanine derivatives
US20040138103A1 (en) 2002-11-07 2004-07-15 Procyte Corporation Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto
IL155111A0 (en) 2003-03-27 2003-10-31 Yerachmiel Yori Applebaum Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
JP4956191B2 (ja) 2003-10-17 2012-06-20 インサイト コーポレーション マトリックスメタロプロテイナーゼの阻害剤としての置換環状ヒドロキサメート
US7871790B2 (en) 2004-03-02 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Anthrax bioassays and methods of treating and diagnosing anthrax infection
WO2005110399A2 (en) 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
CN1950354A (zh) 2004-05-11 2007-04-18 默克公司 N－磺酰化－氨基酸衍生物的制备方法
WO2006073514A2 (en) 2004-08-25 2006-07-13 Tufts University Compositions, methods and kits for repressing virulence in gram positive bacteria

Also Published As

Publication number Publication date
JP4002927B2 (ja) 2007-11-07
IS7517A (is) 2004-10-28
CA2487727C (en) 2011-08-09
DK1511472T3 (da) 2009-08-24
KR100701811B1 (ko) 2007-04-02
EP1511472A4 (en) 2006-09-27
RU2004138595A (ru) 2005-06-10
US7504425B2 (en) 2009-03-17
EP1511472A2 (en) 2005-03-09
PL374117A1 (en) 2005-10-03
MA27257A1 (fr) 2005-03-01
AU2003239599A1 (en) 2003-12-19
BR0311136A (pt) 2007-04-27
IL165259A (en) 2011-02-28
NO20045630L (no) 2005-02-10
SI1511472T1 (sl) 2009-08-31
CN100475206C (zh) 2009-04-08
US20050148629A1 (en) 2005-07-07
CN1655773A (zh) 2005-08-17
ECSP045452A (es) 2005-01-28
RU2289575C2 (ru) 2006-12-20
UA76059C2 (en) 2006-06-15
HRP20041138A2 (en) 2005-04-30
WO2003101382A2 (en) 2003-12-11
AU2003239599B8 (en) 2008-08-14
IL165259A0 (en) 2005-12-18
ZA200408650B (en) 2006-07-26
CA2487727A1 (en) 2003-12-11
DE60327432D1 (de) 2009-06-10
ES2323527T3 (es) 2009-07-20
NO329290B1 (no) 2010-09-27
PT1511472E (pt) 2009-07-24
JP2005534643A (ja) 2005-11-17
WO2003101382A3 (en) 2004-07-29
ATE429909T1 (de) 2009-05-15
NZ536189A (en) 2007-08-31
AU2003239599B2 (en) 2008-07-17
KR20050004250A (ko) 2005-01-12
EP1511472B1 (en) 2009-04-29
MXPA04011767A (es) 2005-03-31

Similar Documents

Publication Publication Date Title
CY1109245T1 (el) Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα
ATE368031T1 (de) Neue gamma secretase inhibitoren
MXPA04012965A (es) Inhibidores virales.
BRPI0413746A (pt) composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
EA200501700A1 (ru) Применение эффектов глутаминил- и глутаматциклаз
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
ECSP055809A (es) Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
HK1085675A1 (en) Anticancer compounds
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
MXPA05010020A (es) Derivados de oxamida.
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
TW200640464A (en) Pharmaceutical composition comprising phenoxazinium compounds as an active ingredient
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht
DE60305520D1 (de) 2" oxo-voruscharin und derivaten
TH79237A (th) สารยับยั้งไกเรส และการใช้สารนี้
MY158057A (en) Viral inhibitors